QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, and pharmacokinetic profiles of AMG 479 when used in
combination with bevacizumab, sorafenib, panitumumab, erlotinib, or gemcitabine in subjects
with advanced solid tumors. Up to 126 subjects may be enrolled. Sorafenib and erlotinib combo
cohorts are enrolling. All other combo cohorts are closed to enrollment.